Amyloid and Tau Imaging Advances at AAIC 2026
Executive Summary
The Alzheimer's Association International Conference (AAIC) 2026 showcased transformative advances in molecular neuroimaging for Alzheimer's disease, featuring:
- Second-generation amyloid PET tracers with improved quantification and simplified clinical workflows
- Next-generation tau PET agents with reduced off-target binding and broader disease applicability
- FDA approval progress for blood-based p-tau biomarkers (p-tau217, p-tau181)
- Integrated biomarker platforms combining PET imaging with fluid biomarkers for comprehensive assessment
- Clinical implementation frameworks enabling point-of-care testing in primary care settings
These advances represent a paradigm shift toward biologically-defined AD diagnosis and treatment selection, moving beyond clinical criteria alone.
Amyloid PET Imaging Advances
Evolution of Amyloid Radiotracers
Amyloid PET has evolved significantly since the introduction of Pittsburgh Compound-B (PiB) in 2004[@klunk2004]:
| Generation | Tracers | Key Advances |
|------------|---------|--------------|
| First-generation | 11C-PiB, 18F-florbetapir, 18F-flutemetamol, 18F-florbetaben | Clinical approval, validation |
| Second-generation | Improved 18F-tracers with better kinetics | Faster clearance, reduced off-target |
Centiloid Scale Standardization
The Centiloid (CL) scale has become the standard metric for amyloid quantification[@navitsky2018]:
...Amyloid and Tau Imaging Advances at AAIC 2026
Executive Summary
The Alzheimer's Association International Conference (AAIC) 2026 showcased transformative advances in molecular neuroimaging for Alzheimer's disease, featuring:
- Second-generation amyloid PET tracers with improved quantification and simplified clinical workflows
- Next-generation tau PET agents with reduced off-target binding and broader disease applicability
- FDA approval progress for blood-based p-tau biomarkers (p-tau217, p-tau181)
- Integrated biomarker platforms combining PET imaging with fluid biomarkers for comprehensive assessment
- Clinical implementation frameworks enabling point-of-care testing in primary care settings
These advances represent a paradigm shift toward biologically-defined AD diagnosis and treatment selection, moving beyond clinical criteria alone.
Amyloid PET Imaging Advances
Evolution of Amyloid Radiotracers
Amyloid PET has evolved significantly since the introduction of Pittsburgh Compound-B (PiB) in 2004[@klunk2004]:
| Generation | Tracers | Key Advances |
|------------|---------|--------------|
| First-generation | 11C-PiB, 18F-florbetapir, 18F-flutemetamol, 18F-florbetaben | Clinical approval, validation |
| Second-generation | Improved 18F-tracers with better kinetics | Faster clearance, reduced off-target |
Centiloid Scale Standardization
The Centiloid (CL) scale has become the standard metric for amyloid quantification[@navitsky2018]:
- 0 CL: Mean signal in young healthy individuals (negative for amyloid)
- 100 CL: Mean signal in typical AD patients
- Threshold: >20-25 CL typically considered amyloid-positive
- Clinical cutoff: Often set at 30 CL for treatment decisions
Mermaid diagram (expand to render)
Second-Generation Amyloid Tracers
AAIC 2026 featured advances in amyloid PET technology:
| Tracer | Characteristics | Status |
|--------|-----------------|--------|
| 18F-Florbetapir (Amyvid) | FDA-approved, widely used | Clinical standard |
| 18F-Flutemetamol (Vizamyl) | FDA-approved, thioflavin analog | Clinical standard |
| 18F-Florbetaben (Neuraceq) | FDA-approved for beta-amyloid | Clinical standard |
| 18F-AK01 | Improved signal-to-noise | Phase 3 |
Amyloid PET in Anti-Amyloid Therapy
Amyloid PET is essential for patient selection and treatment monitoring:
| Therapy | Amyloid PET Requirement | Monitoring |
|---------|------------------------|------------|
| Lecanemab (Leqembi) | Amyloid-positive MCI or AD | SUVr reduction at 18 months |
| Donanemab | Amyloid-positive early AD | Plaque clearance (CL < 10) |
| Aducanumab | Amyloid-positive AD | Dose selection, target engagement |
Tau PET Imaging Advances
First vs. Second-Generation Tau Tracers
AAIC 2026 highlighted the transition from first to second-generation tau PET agents[@fleisher2024]:
| Property | First-Generation | Second-Generation |
|----------|-------------------|-------------------|
| Off-target binding | High (basal ganglia, choroid plexus) | Minimal |
| Quantification | Complex SUVr methods | Simplified visual read |
| Disease applicability | AD only | AD + primary tauopathies |
| Early detection | Limited | Preclinical detection |
Key Tau PET Tracers
FDA-Approved
Flortaucipir (Tauvid, 18F-AV-1451)
- First and only FDA-approved tau PET tracer
- Indicated for amyloid-positive adults with MCI or dementia due to AD
- Acquisition: 80-100 minutes post-injection
- Limitations: Off-target binding in basal ganglia, limited 3R/4R detection
Second-Generation in Development
| Tracer | Developer | Key Features | Status |
|--------|-----------|--------------|--------|
| MK-6240 | Merck | Higher PHF-tau specificity | Phase 3 |
| PI-2620 | Life Molecular Imaging | 3R/4R detection (PSP, CBD) | Phase 2/3 |
| APN-1607 | Aprinoia | Broad tauopathy applicability | Phase 2 |
| RO-948 | Roche | Early detection | Phase 2 |
| JNJ-311 | J&J | Novel binding profile | Phase 1 |
Tau PET Disease Staging
Tau PET enables in vivo Braak staging:
| Braak Stage | Regions Affected | Clinical Correlation |
|-------------|------------------|---------------------|
| I-II | Transentorhinal cortex | Preclinical AD |
| III-IV | Limbic (hippocampus, entorhinal) | MCI to mild AD |
| V-VI | Isocortical (frontal, parietal) | Moderate to severe AD |
Tau PET in Clinical Trials
Tau PET serves as both enrichment biomarker and outcome measure:
| Trial Phase | Tau PET Application |
|-------------|---------------------|
| Phase 1 | Target engagement, dose selection |
| Phase 2 | Patient stratification, mechanism validation |
| Phase 3 | Disease modification endpoints |
AAIC 2026 Anti-Tau Updates:
- Semorinemab (Roche): Phase 2 showed tau PET reduction in temporal cortex
- Zagotenemab (Eli Lilly): Mid-domain targeting showing promising results
- JNJ-63733657 (J&J): Phospho-tau specific antibody in Phase 1
Fluid Biomarker Integration
Blood-Based Biomarker Advances
AAIC 2026 featured major advances in blood-based biomarkers[@palmqvist2024]:
| Biomarker | Current Status | Clinical Utility |
|-----------|----------------|------------------|
| p-Tau217 | FDA review pending | Highest specificity, >95% sensitivity |
| p-Tau181 | FDA-cleared (multiple platforms) | Widely available, screening |
| p-Tau231 | Research stage | Earliest detectable marker |
| GFAP | FDA-cleared | Astrocyte activation, amyloid reactivity |
Blood biomarkers demonstrate exceptional performance[@blennow2024]:
| Panel Composition | AUC for AD vs. Controls |
|-------------------|------------------------|
| p-tau217 + GFAP | 0.95-0.97 |
| p-tau181 + NfL | 0.92-0.94 |
| p-tau217 + GFAP + NfL | 0.96-0.98 |
| p-tau217 + GFAP + Aβ42/40 | 0.97-0.99 |
PET-Fluid Biomarker Correlation
| PET Measure | Fluid Biomarker Correlation |
|-------------|----------------------------|
| Amyloid PET (Centiloid) | p-tau217 (r=0.82-0.89), Aβ42/40 (r=0.75-0.85) |
| Tau PET (Braak ROI) | p-tau217 (r=0.78-0.86), p-tau181 (r=0.70-0.80) |
| Neurodegeneration (FDG-PET) | NfL (r=0.65-0.75), p-tau181 (r=0.60-0.70) |
AT(N) Framework Evolution
Expansion to Blood-Based Biomarkers
The AT(N) framework has evolved to incorporate blood-based markers[@jack2022]:
Mermaid diagram (expand to render)
- AT(Blood): Blood-based amyloid, tau, neurodegeneration markers
- Combined panels: All AT(N) markers from single blood draw
- Multimodal integration: PET + MRI + fluid biomarker combinations
Clinical Decision Framework
| Scenario | Recommended Biomarkers |
|----------|----------------------|
| Routine screening | p-tau181 (primary care) |
| Confirmatory testing | p-tau217 (specialty) |
| Comprehensive assessment | Full AT(N) panel + PET |
| Treatment selection | Amyloid PET required |
| Treatment monitoring | p-tau217, NfL, amyloid PET |
Clinical Implementation
Regulatory Status
FDA pathway updates:
- Multiple p-tau assays under FDA review (2026-2027 decisions expected)
- FDA guidance on validation requirements published
- Medicare coverage pending FDA clearance
Implementation Framework
Two-tiered clinical approach:
Initial screening: p-tau181 in primary care
Confirmatory testing: p-tau217 for complex cases
Comprehensive assessment: Full biomarker panel in specialized settingsHealth Equity Considerations
- Ancestry-specific cutoffs validated in diverse populations
- Point-of-care testing for under-resourced settings
- Dried blood spot approaches for broader access
Future Directions
Emerging Technologies
| Technology | Potential Impact |
|-------------|------------------|
| Point-of-care lateral flow assays | Primary care screening |
| Dried blood spot testing | Broader accessibility |
| Tau oligomer detection | Earlier, more specific detection |
| Exosomal tau | Brain-region specific signals |
Research Priorities
Standardization: Cross-platform harmonization
Accessibility: Point-of-care testing
Integration: Electronic health record incorporation
Education: Clinician training on appropriate use
Related NeuroWiki Content
Biomarker Pages
- [Amyloid PET Imaging](/biomarkers/amyloid-pet-imaging)
- [Tau PET Imaging](/biomarkers/tau-pet-imaging)
- [p-Tau217](/biomarkers/p-tau-217)
- [p-Tau181](/biomarkers/p-tau-181)
- [GFAP](/biomarkers/gfap-alzheimers)
- [Blood-Based Biomarkers](/mechanisms/blood-based-biomarkers)
- [AT(N) Biomarker Classification](/mechanisms/alzheimers-disease-biomarker-temporal-sequence-hypothesis)
Therapeutic Pages
- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-therapeutics)
- [Lecanemab](/therapeutics/lecanemab)
- [Anti-Tau Immunotherapy](/therapeutics/anti-tau-immunotherapies)
- [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)
Event Content
- [AAIC 2026 Conference](/events/aaic-2026)
- [AAIC 2026: Tau Imaging and Biomarker Validation](/events/aaic-2026-tau-imaging-biomarker-validation)
- [AAIC 2026: Fluid Biomarkers](/events/aaic-2026/fluid-biomarkers)
References
[Klunk WE, et al., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B (PiB) (2004)](https://doi.org/10.1093/brain/awh349)
[Navitsky M, et al., Standardization of amyloid quantitation with florbetapir PET to the Centiloid scale (2018)](https://doi.org/10.1016/j.neuroimage.2018.06.079)
[Mintun MA, et al., FLORTauCIPIR (F 18 AV-1451) PET imaging in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32031504/)
[Fleisher AS, et al., Tau PET imaging: optimizing detection and quantification (2024)](https://pubmed.ncbi.nlm.nih.gov/38942015/)
[Palmqvist S, et al., Performance of Fully Automated Plasma p-Tau217 Assays as Screening Tests for Alzheimer Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38597015/)
[Jack CR Jr, et al., AT(N): A Research Framework for Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35645193/)
[Blennow K, et al., Blood biomarkers for Alzheimer's disease: current status and future directions (2024)](https://pubmed.ncbi.nlm.nih.gov/38456347/)
[Cummings J, et al., Alzheimer's disease drug development pipeline: 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)